Literature DB >> 26884875

Serum Interleukin-33 level in Saudi children with inflammatory bowel disease.

Omar I Saadah1, Sameer E Al-Harthi2, Jamil A Al-Mughales3, Yagoub Y Bin-Taleb4, Raed S Baeshen5.   

Abstract

Interleukin-33 (IL-33) is a cytokine that belongs to the interleukin-1 family and has been shown to be associated with mucosal inflammation. The aim of this study was to determine the serum level of IL-33 in children with ulcerative colitis (UC) and Crohn's disease (CD) and to correlate the level with the disease progression. In this cross sectional prospective study, we enrolled 50 children with IBD from KAUH, Jeddah, Saudi Arabia and 34 healthy control subjects between June 2012 and December 2012. Serum IL-33 was assessed by ELISA and CRP by immunonephelometric assay. Results from our study showed 32 CD and 18 UC patients included. The median age was 13.5 years for CD patients, 11.9 years for UC patients and 11.2 years for controls. Females constituted 53%, 66.7% and 59% of CD, UC and control subjects respectively. The median serum IL-33 in UC patients of 55.5 pg/mL was significantly higher than the median IL-33 level of 41 pg/mL in the healthy control (P=0.04) but no significant difference was found between the median IL-33 level in the sera of CD and the control group (P=0.7). A higher median IL-33 level was also found in active disease (P=0.03). In our cohort, the serum level of IL-33 was positively correlated with hs-CRP (r=0.48, P < 0.001). To conclude, our results support that serum IL-33 level is increased in children with UC as compared with control. Serum level is correlated with the disease activity; therefore it could be used as a potential biomarker for monitoring the severity of the disease in children with UC.

Entities:  

Keywords:  Crohn’s disease (CD); IL-33; Saudi Arabia; children; ulcerative colitis (UC)

Mesh:

Substances:

Year:  2015        PMID: 26884875      PMCID: PMC4730088     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  36 in total

1.  Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging.

Authors:  A H Gitter; F Wullstein; M Fromm; J D Schulzke
Journal:  Gastroenterology       Date:  2001-12       Impact factor: 22.682

2.  Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria.

Authors: 
Journal:  J Pediatr Gastroenterol Nutr       Date:  2005-07       Impact factor: 2.839

3.  Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis.

Authors:  Jesús Rivera-Nieves; Giorgos Bamias; Alda Vidrich; Marco Marini; Theresa T Pizarro; Marcia J McDuffie; Christopher A Moskaluk; Steven M Cohn; Fabio Cominelli
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

4.  Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis.

Authors:  Luca Pastorelli; Rekha R Garg; Sharon B Hoang; Luisa Spina; Benedetta Mattioli; Melania Scarpa; Claudio Fiocchi; Maurizio Vecchi; Theresa T Pizarro
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

5.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications.

Authors:  J Satsangi; M S Silverberg; S Vermeire; J-F Colombel
Journal:  Gut       Date:  2006-06       Impact factor: 23.059

6.  IL-33 activates B1 cells and exacerbates contact sensitivity.

Authors:  Mousa Komai-Koma; Derek S Gilchrist; Andrew N J McKenzie; Carl S Goodyear; Damo Xu; Foo Y Liew
Journal:  J Immunol       Date:  2011-01-14       Impact factor: 5.422

Review 7.  The role of the Interleukin 1 receptor-like 1 (ST2) and Interleukin-33 pathway in cardiovascular disease and cardiovascular risk assessment.

Authors:  S Willems; I Hoefer; G Pasterkamp
Journal:  Minerva Med       Date:  2012-12       Impact factor: 4.806

8.  Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.

Authors:  Athos Bousvaros; Donald A Antonioli; Richard B Colletti; Marla C Dubinsky; Jonathan N Glickman; Benjamin D Gold; Anne M Griffiths; Gareth P Jevon; Leslie M Higuchi; Jeffrey S Hyams; Barbara S Kirschner; Subra Kugathasan; Robert N Baldassano; Pierre A Russo
Journal:  J Pediatr Gastroenterol Nutr       Date:  2007-05       Impact factor: 2.839

9.  Beneficial effect of anti-interleukin-33 on the murine model of allergic inflammation of the lower airway.

Authors:  Young Hyo Kim; Chang-Shin Park; Dae Hyun Lim; Sung-Hye Ahn; Byong Kwan Son; Jeong Hee Kim; Tae Young Jang
Journal:  J Asthma       Date:  2012-07-17       Impact factor: 2.515

Review 10.  The evolutionary role of the IL-33/ST2 system in host immune defence.

Authors:  Susanne Sattler; Hermelijn H Smits; Damo Xu; Fang-Ping Huang
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-01-03       Impact factor: 4.291

View more
  2 in total

1.  IL-33 promotes the egress of group 2 innate lymphoid cells from the bone marrow.

Authors:  Matthew T Stier; Jian Zhang; Kasia Goleniewska; Jacqueline Y Cephus; Mark Rusznak; Lan Wu; Luc Van Kaer; Baohua Zhou; Dawn C Newcomb; R Stokes Peebles
Journal:  J Exp Med       Date:  2017-12-08       Impact factor: 14.307

2.  Alarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis Vulgaris.

Authors:  Pavel Borsky; Zdenek Fiala; Ctirad Andrys; Martin Beranek; Kvetoslava Hamakova; Andrea Malkova; Tereza Svadlakova; Jan Krejsek; Vladimir Palicka; Lenka Borska; Vit Rehacek
Journal:  Mediators Inflamm       Date:  2020-04-15       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.